Free Trial

MoonLake Immunotherapeutics (MLTX) Competitors

MoonLake Immunotherapeutics logo
$38.51 -0.03 (-0.08%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$38.49 -0.02 (-0.05%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MLTX vs. MRNA, QGEN, ASND, ROIV, RVMD, BBIO, BPMC, ELAN, LEGN, and TGTX

Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

MoonLake Immunotherapeutics vs.

Moderna (NASDAQ:MRNA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Moderna has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Moderna received 144 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 81.82% of users gave MoonLake Immunotherapeutics an outperform vote while only 53.20% of users gave Moderna an outperform vote.

CompanyUnderperformOutperform
ModernaOutperform Votes
216
53.20%
Underperform Votes
190
46.80%
MoonLake ImmunotherapeuticsOutperform Votes
72
81.82%
Underperform Votes
16
18.18%

In the previous week, Moderna had 13 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 34 mentions for Moderna and 21 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.13 beat Moderna's score of 0.62 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Moderna
15 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
7 Negative mention(s)
0 Very Negative mention(s)
Positive
MoonLake Immunotherapeutics
9 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Moderna's net margin of -110.04%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Moderna-110.04% -28.74% -21.83%
MoonLake Immunotherapeutics N/A -15.54%-15.09%

75.3% of Moderna shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 11.0% of Moderna shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Moderna currently has a consensus target price of $53.58, indicating a potential upside of 100.52%. MoonLake Immunotherapeutics has a consensus target price of $78.71, indicating a potential upside of 104.40%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna
4 Sell rating(s)
15 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.04
MoonLake Immunotherapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

MoonLake Immunotherapeutics has lower revenue, but higher earnings than Moderna. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$3.14B3.29-$3.56B-$8.73-3.06
MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$2.30-16.74

Summary

MoonLake Immunotherapeutics beats Moderna on 12 of the 18 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLTX vs. The Competition

MetricMoonLake ImmunotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.47B$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-29.859.0626.7919.70
Price / SalesN/A259.83393.69121.79
Price / CashN/A65.8538.2534.62
Price / Book4.736.456.774.50
Net Income-$36.01M$143.98M$3.23B$248.22M
7 Day Performance2.37%0.38%0.42%-0.80%
1 Month Performance-2.53%2.14%9.06%11.52%
1 Year Performance-3.63%-0.33%18.55%8.99%

MoonLake Immunotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLTX
MoonLake Immunotherapeutics
3.2901 of 5 stars
$38.51
-0.1%
$78.71
+104.4%
-3.5%$2.47BN/A-29.852Positive News
MRNA
Moderna
4.4415 of 5 stars
$25.70
+6.0%
$53.95
+109.9%
-83.6%$9.94B$3.14B-2.773,900Trending News
Analyst Forecast
QGEN
Qiagen
3.9784 of 5 stars
$42.92
+2.5%
$48.42
+12.8%
+0.1%$9.54B$1.98B119.526,030Positive News
ASND
Ascendis Pharma A/S
3.3776 of 5 stars
$154.43
+2.1%
$216.07
+39.9%
+22.0%$9.42B$368.70M-21.75640Positive News
ROIV
Roivant Sciences
2.1118 of 5 stars
$10.99
+3.3%
$17.50
+59.2%
-3.1%$7.84B$122.59M-73.26860Positive News
Upcoming Earnings
Insider Trade
RVMD
Revolution Medicines
4.3594 of 5 stars
$41.88
+3.6%
$67.17
+60.4%
-2.4%$7.80B$742,000.00-11.67250Positive News
BBIO
BridgeBio Pharma
4.604 of 5 stars
$35.68
+4.4%
$57.09
+60.0%
+12.6%$6.77B$127.42M-12.52400Insider Trade
BPMC
Blueprint Medicines
2.6022 of 5 stars
$100.31
+3.2%
$126.56
+26.2%
-2.3%$6.48B$562.12M-92.88640Positive News
Insider Trade
ELAN
Elanco Animal Health
3.2148 of 5 stars
$12.82
+7.2%
$15.00
+17.0%
-25.1%$6.36B$4.43B32.049,800Gap Up
LEGN
Legend Biotech
3.522 of 5 stars
$32.38
+1.9%
$78.82
+143.4%
-31.8%$5.95B$627.24M-34.081,070Gap Up
TGTX
TG Therapeutics
3.8093 of 5 stars
$34.99
+4.0%
$40.80
+16.6%
+93.4%$5.56B$386.39M-349.87290Positive News

Related Companies and Tools


This page (NASDAQ:MLTX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners